Feb 18, 2026 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.

Dec 31, 2025 · “Last year was a defining year for Harrow, with revenue up 36% for the year and a record fourth quarter that reflected both accelerating demand and improving operating leverage, especially …

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance …

Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year.

Harrow has acquired global rights to MELT-300 and MELT-210, and contracted for the U.S. commercial rights to BYQLOVI™, BYOOVIZ®, and OPUVIZ™. These products will be added to this section once …

Feb 2, 2026 · As part of OneHarrow, all Harrow products, including its compounded formulations, will be marketed and sold through under the Harrow brand by a unified organization that is more aligned, …

In September 2025, Harrow announced the launch of Harrow Access for All (HAFA), expanding Harrow’s commitment to make it easier and more affordable for patients to access Harrow’s full …

Mar 3, 2026 · TRIESENCE is central to this strategy and reinforces Harrow’s commitment to advancing a more efficient, patient-focused cataract surgery paradigm. “This study marks an important …

Dec 31, 2024 · Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical …

At Harrow, we’re passionate about making eyecare more innovative, accessible, and affordable for everyone. Whether you're an eyecare professional, a patient, or a current — or future — member of …